London, UK-based Rexgenero has reached a major milestone in treating the first patient in a late-stage trial with its lead product, cell therapy REX-001.
News
NICE/PHE against blanket use of antibiotics for sore throats
Sore throats should be treated with painkillers and not antibiotics, according to new guidelines produced by the National Institute for Health and Care Excellence and Public Health England.
Novartis buys access to Spark’s vision loss therapy
Novartis has bought itself rights to Spark Therapeutic’s gene therapy for a certain type of vision loss, in a deal worth up to $170 million.
Lancet-published data show potential of GW’s Epidiolex
The Lancet has published data from a Phase III study backing use of GW Pharmaceutical/Greenwich Bioscience’s Epidiolex in patients with Lennox-Gastaut syndrome (LGS).
AZ enrolls first patient in Brilinta stroke trial
Brilinta (ticagrelor) is approved for the treatment of acute coronary syndromes and prevention of further coronary events in patients at high-risk following a heart attack.
First-line use of lung cancer drug Zykadia gets NHS nod
Final guidelines have now been published endorsing NHS use of Novartis’ Zykadia as a first line of attack for anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC), offering patients a new treatment option.
UK charity gives US biotech $1m for Parkinson’s research
UK charity Parkinson’s UK is handing over more than $1 million in funding to US biotech company Neurolixis, to help fuel development of a novel, experimental therapy for patients with Parkinson’s disease.
Cobra awarded £2.6m from Innovate UK for expansion
Keele, UK-based Cobra Biologics is being handed £2.6 million by Innovate UK to help the firm expand and develop its infrastructure.
Mylan launches Copaxone generic in the UK
Mylan has launched in the UK the first generic formulation of Teva’s multiple sclerosis blockbuster Copaxone, offering a potentially cheaper alternative for treatment of relapsing forms of the condition.
PHE to review prescription drug addiction in the UK
The government has launched what it describes as a “landmark” independent review into prescription drug addiction in the UK.
NICE backs trial of online programme for depression
The National Institute for Health and Care Excellence has given its backing for an online programme to be trialed on the NHS for the treatment of depression.
Lilly’s Taltz wins EU approval for psoriatic arthritis
Eli Lilly has been given a green light to market Taltz in the European Union as a treatment for psoriatic arthritis.
Teva’s subcutaneous asthma drug fails in PhIII
Teva’s quest to expand approval of its respiratory drug Cinquair/Cinqaero with a new mode of delivery has hit a snag, after two late-stage studies failed to hit their targets.
Rexgenero wins £1.4m grant from Innovate UK
London, UK-based Rexgenero has secured with partners £1.4 million in funding for a £1.8 million project from the UK’s innovation agency Innovate UK, for an industrial research project on the commercial manufacture of its product REX-001.
Astellas bags orphan drug status for AML drug
Astellas’ experimental acute myeloid leukaemia drug gilteritinib has been awarded orphan drug designation by the European Commission.
